A major challenge limiting the therapeutic efficacy of CAR T cell therapies in solid tumors is the TME, which comprises various immunosuppressive cells that highjack the PD-1/PD-L1 cascade to inhibit T cell function, allowing tumor cells to evade antitumor immunity.2 This evidence concerns the gene CD274 and neoplasm.